By the same authors

From the same journal

From the same journal

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

Research output: Contribution to journalLiterature review

Standard

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. / Collins, Ros; Trowman, R.; Norman, G.; Light, K.; Birtle, A.; Fenwick, E.; Palmer, S.; Riemsma, R.

In: British journal of cancer, Vol. 95, No. 4, 21.08.2006, p. 457-462.

Research output: Contribution to journalLiterature review

Harvard

Collins, R, Trowman, R, Norman, G, Light, K, Birtle, A, Fenwick, E, Palmer, S & Riemsma, R 2006, 'A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer', British journal of cancer, vol. 95, no. 4, pp. 457-462. https://doi.org/10.1038/sj.bjc.6603287

APA

Collins, R., Trowman, R., Norman, G., Light, K., Birtle, A., Fenwick, E., ... Riemsma, R. (2006). A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. British journal of cancer, 95(4), 457-462. https://doi.org/10.1038/sj.bjc.6603287

Vancouver

Collins R, Trowman R, Norman G, Light K, Birtle A, Fenwick E et al. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. British journal of cancer. 2006 Aug 21;95(4):457-462. https://doi.org/10.1038/sj.bjc.6603287

Author

Collins, Ros ; Trowman, R. ; Norman, G. ; Light, K. ; Birtle, A. ; Fenwick, E. ; Palmer, S. ; Riemsma, R. / A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. In: British journal of cancer. 2006 ; Vol. 95, No. 4. pp. 457-462.

Bibtex - Download

@article{2db775b1a4a7428a8b725d3fa1ba27ac,
title = "A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer",
abstract = "A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone ( docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer. A scoping search identified a trial of docetaxel plus prednisone vs mitoxantrone plus prednisone, but did not identify any trials comparing docetaxel plus prednisolone/prednisone with any other treatments. Therefore, we considered additional indirect evidence that would enable a comparison of docetaxel plus prednisolone/prednisone with other chemotherapy regimens and active supportive care. Systematic searching (upto April 2005) identified seven randomised controlled trials. One large well-conducted trial assessed docetaxel plus prednisone vs mitoxantrone plus prednisone; this showed statistically significant improvements with 3-weekly docetaxel in terms of overall survival, quality of life, pain response and PSA decline. Two other chemotherapy regimens that included docetaxel with estramustine also showed improved outcomes in comparison with mitoxantrone plus prednisone. Three trials that compared mitoxantrone plus corticosteroids with corticosteroids alone were identified and their results for overall survival combined, which showed very little difference between the two groups. The addition of clodronate to mitoxantrone plus prednisone showed no significant differences in comparison with mitoxantrone plus prednisone alone. The evidence suggests that chemotherapy regimens containing 3-weekly docetaxel are superior to mitoxantrone or corticosteroids alone.",
keywords = "hormone-refractory prostate cancer, docetaxel, mitoxantrone, systematic review, PLUS PREDNISONE, ESTRAMUSTINE, TRIAL",
author = "Ros Collins and R. Trowman and G. Norman and K. Light and A. Birtle and E. Fenwick and S. Palmer and R. Riemsma",
year = "2006",
month = "8",
day = "21",
doi = "10.1038/sj.bjc.6603287",
language = "English",
volume = "95",
pages = "457--462",
journal = "British journal of cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

AU - Collins, Ros

AU - Trowman, R.

AU - Norman, G.

AU - Light, K.

AU - Birtle, A.

AU - Fenwick, E.

AU - Palmer, S.

AU - Riemsma, R.

PY - 2006/8/21

Y1 - 2006/8/21

N2 - A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone ( docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer. A scoping search identified a trial of docetaxel plus prednisone vs mitoxantrone plus prednisone, but did not identify any trials comparing docetaxel plus prednisolone/prednisone with any other treatments. Therefore, we considered additional indirect evidence that would enable a comparison of docetaxel plus prednisolone/prednisone with other chemotherapy regimens and active supportive care. Systematic searching (upto April 2005) identified seven randomised controlled trials. One large well-conducted trial assessed docetaxel plus prednisone vs mitoxantrone plus prednisone; this showed statistically significant improvements with 3-weekly docetaxel in terms of overall survival, quality of life, pain response and PSA decline. Two other chemotherapy regimens that included docetaxel with estramustine also showed improved outcomes in comparison with mitoxantrone plus prednisone. Three trials that compared mitoxantrone plus corticosteroids with corticosteroids alone were identified and their results for overall survival combined, which showed very little difference between the two groups. The addition of clodronate to mitoxantrone plus prednisone showed no significant differences in comparison with mitoxantrone plus prednisone alone. The evidence suggests that chemotherapy regimens containing 3-weekly docetaxel are superior to mitoxantrone or corticosteroids alone.

AB - A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone ( docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer. A scoping search identified a trial of docetaxel plus prednisone vs mitoxantrone plus prednisone, but did not identify any trials comparing docetaxel plus prednisolone/prednisone with any other treatments. Therefore, we considered additional indirect evidence that would enable a comparison of docetaxel plus prednisolone/prednisone with other chemotherapy regimens and active supportive care. Systematic searching (upto April 2005) identified seven randomised controlled trials. One large well-conducted trial assessed docetaxel plus prednisone vs mitoxantrone plus prednisone; this showed statistically significant improvements with 3-weekly docetaxel in terms of overall survival, quality of life, pain response and PSA decline. Two other chemotherapy regimens that included docetaxel with estramustine also showed improved outcomes in comparison with mitoxantrone plus prednisone. Three trials that compared mitoxantrone plus corticosteroids with corticosteroids alone were identified and their results for overall survival combined, which showed very little difference between the two groups. The addition of clodronate to mitoxantrone plus prednisone showed no significant differences in comparison with mitoxantrone plus prednisone alone. The evidence suggests that chemotherapy regimens containing 3-weekly docetaxel are superior to mitoxantrone or corticosteroids alone.

KW - hormone-refractory prostate cancer

KW - docetaxel

KW - mitoxantrone

KW - systematic review

KW - PLUS PREDNISONE

KW - ESTRAMUSTINE

KW - TRIAL

U2 - 10.1038/sj.bjc.6603287

DO - 10.1038/sj.bjc.6603287

M3 - Literature review

VL - 95

SP - 457

EP - 462

JO - British journal of cancer

T2 - British journal of cancer

JF - British journal of cancer

SN - 0007-0920

IS - 4

ER -